thalidomide has been researched along with von Willebrand Diseases in 7 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
von Willebrand Diseases: Group of hemorrhagic disorders in which the VON WILLEBRAND FACTOR is either quantitatively or qualitatively abnormal. They are usually inherited as an autosomal dominant trait though rare kindreds are autosomal recessive. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII, and impaired platelet adhesion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to present a new case on the successful use of thalidomide in a patient with acquired von Willebrand syndrome and recurrent angiodysplasia-related GI bleedings, and to conduct a literature review on the use of thalidomide in patients with GI angiodysplasia." | 8.91 | Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature. ( Engelen, ET; Schutgens, RE; van Galen, KP, 2015) |
| " Thalidomide has emerged as a promising medical strategy in angiodysplasia-related bleeding." | 8.91 | Thalidomide in angiodysplasia-related bleeding. ( Boey, JP; Hahn, U; McRae, SJ; Sagheer, S, 2015) |
| "Lenalidomide is a thalidomide analog with anti-angiogenic properties." | 5.48 | Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease. ( Bull-Henry, K; Kessler, CM; Khatri, NV; Kohli, DR; Patel, B; Solomon, SS, 2018) |
| "An 80-year-old man with von Willebrand's disease was admitted with severe melaena." | 5.33 | Thalidomide as treatment for digestive tract angiodysplasias. ( Brouwer, RE; Heidt, J; Langers, AM; van der Meer, FJ, 2006) |
| "The aim of this study was to present a new case on the successful use of thalidomide in a patient with acquired von Willebrand syndrome and recurrent angiodysplasia-related GI bleedings, and to conduct a literature review on the use of thalidomide in patients with GI angiodysplasia." | 4.91 | Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature. ( Engelen, ET; Schutgens, RE; van Galen, KP, 2015) |
| " Thalidomide has emerged as a promising medical strategy in angiodysplasia-related bleeding." | 4.91 | Thalidomide in angiodysplasia-related bleeding. ( Boey, JP; Hahn, U; McRae, SJ; Sagheer, S, 2015) |
| "Lenalidomide is a thalidomide analog with anti-angiogenic properties." | 1.48 | Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease. ( Bull-Henry, K; Kessler, CM; Khatri, NV; Kohli, DR; Patel, B; Solomon, SS, 2018) |
| "Lenalidomide is a potential treatment option for refractory bleeding in AVWS secondary to MG." | 1.43 | Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy. ( Brophy, TM; Browne, PV; Hayden, PJ; Lavin, M; O'Connell, N; O'Donnell, JS; O'Sullivan, JM; Rawley, O; Ryan, K, 2016) |
| "An 80-year-old man with von Willebrand's disease was admitted with severe melaena." | 1.33 | Thalidomide as treatment for digestive tract angiodysplasias. ( Brouwer, RE; Heidt, J; Langers, AM; van der Meer, FJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khatri, NV | 1 |
| Patel, B | 1 |
| Kohli, DR | 1 |
| Solomon, SS | 1 |
| Bull-Henry, K | 1 |
| Kessler, CM | 1 |
| Engelen, ET | 1 |
| van Galen, KP | 1 |
| Schutgens, RE | 1 |
| Boey, JP | 1 |
| Hahn, U | 1 |
| Sagheer, S | 1 |
| McRae, SJ | 1 |
| Lavin, M | 1 |
| Brophy, TM | 1 |
| Rawley, O | 1 |
| O'Sullivan, JM | 1 |
| Hayden, PJ | 1 |
| Browne, PV | 1 |
| Ryan, K | 1 |
| O'Connell, N | 1 |
| O'Donnell, JS | 1 |
| Ouyang, HY | 1 |
| Yu, ZJ | 1 |
| Yin, J | 1 |
| Zhao, XJ | 1 |
| Wang, ZY | 1 |
| Zhang, W | 1 |
| Ma, ZN | 1 |
| Su, J | 1 |
| Bai, X | 1 |
| Ruan, CG | 1 |
| Hirri, HM | 1 |
| Green, PJ | 1 |
| Lindsay, J | 1 |
| Heidt, J | 1 |
| Langers, AM | 1 |
| van der Meer, FJ | 1 |
| Brouwer, RE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Type 3 Von Willebrand International Registries Inhibitor Prospective Study[NCT02460458] | 265 participants (Actual) | Observational | 2012-11-05 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measurement of Factor VIII (FVIII) Amidolytic Activity (FVIII:Am) in the blood through chromogenic test. Only patients with FVIII:Am less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.63 |
Measurement of the amount of Factor VIII (FVIII) protein in the blood through FVIII:Ag test. Only patients with FVIII:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 3.64 |
Measurement of the Factor VIII (FVIII) Procoagulant Activity (FVIII:C) in the blood through one-stage clotting test. Only patients with FVIII:C less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 2.43 |
Measurement of Von Willebrand Factor (VWF) Propeptide levels in the blood through VWF Propeptide test. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 7.3 |
Measurement of the amount of Von Willebrand Factor (VWF) protein in the blood through Von Willebrand Factor Antigen (VWF:Ag) test. Only patients with VWF:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.29 |
"Number of patients for who the following tests have been performed:~Hemoglobin (mmol/L), Hemagglutination Titer (HT) (%), Mean Corpuscular Volume (MVC) (fl), Leucocytes (E9/L), Neutrophils (%), Basophils (%), Eosinophils (%), Lymphocytes (%), Platelet Count (E9/L), Mean Platelet Volume (MPV) (fl), Prothrombin Time (sec), Partial Thromboplastin Time (PTT) (sec), Partial Thromboplastin Time Mix 50:50 (PTT mix 50:50) (sec), Ferritin (ug/l), Bleeding Time (min:sec), Closure Time (sec), Collagen/ADP (sec), Collagen/Epinephrine (sec); Factor VIII Procoagulant Activity (FVIII:C) (IU/mL), Von Willebrand Factor Ristocetin Cofactor (VWF:RCo) (IU/mL), Won Willebrand Factor Antigen (VWF:Ag) (IU/mL)." (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 265 |
Evaluation of the titre of Anti-Von Willebrand Factor (anti-VWF) Antibodies through Bethesda Test. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 4 |
Record of any allergic and anaphylactic reactions occurred in the past due to the use of any Von Willebrand Factor (VWF) concentrate and the date of onset. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 41 |
Record of any product used during the retrospective phase (collected type of blood products/Von Willebrand Factor (VWF) concentrate, year of first exposure, units used). (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Packed red cells | Cryoprecipitates | Fresh frozen plasma | Platelet concentrates | |
| Type 3 Von Willebrand's Disease (VWD3) | 24 | 123 | 10 | 1 |
3 reviews available for thalidomide and von Willebrand Diseases
| Article | Year |
|---|---|
Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature.
Topics: Aged; Angiodysplasia; Databases, Factual; Epistaxis; Female; Gastrointestinal Hemorrhage; Humans; Me | 2015 |
Thalidomide in angiodysplasia-related bleeding.
Topics: Aged; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Human | 2015 |
[Acquired von Willebrand syndrome in three patients and literature review].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hemorrhage; Humans; Immunoglobulins, I | 2016 |
4 other studies available for thalidomide and von Willebrand Diseases
| Article | Year |
|---|---|
Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease.
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Female; Humans; Lenalidomide; Male; Retrospective Stu | 2018 |
Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy.
Topics: Aged; Anticoagulants; Drug Administration Schedule; Hemorrhage; Humans; Lenalidomide; Male; Middle A | 2016 |
Von Willebrand's disease and angiodysplasia treated with thalidomide.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Humans; Male; Middle Aged; Thalidomide; Treatment Outcome; | 2006 |
Thalidomide as treatment for digestive tract angiodysplasias.
Topics: Aged, 80 and over; Angiodysplasia; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; L | 2006 |